Company intelligence / Profile preview

Resolve Therapeutics

Miami, Florida, USAresolvetherapeutics.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 2

Overview

Resolve’s lead candidate RSLV‑132 has completed three clinical trials demonstrating safety and symptom improvement in SLE, Sjogren’s syndrome, and long COVID. The company continues to pursue additional indications with high unmet need where nucleic acids drive disease pathology[1].

Therapeutic areas: PulmonologyCardiovascularImmunologyDermatologyHematologyNeurologyInfectious Diseases
Modalities: Nuclease Fc fusion proteins (biologic drugs)
Industry: Biotech

Drug pipeline

3 assets

RSLV-132

2 more assets in the full pipeline.

Request access →

Partnerships

Technology licensed from University of Washingtonplans to partner with pharmaceutical companies for late-stage development/commercialization[4]

Beyond the preview

Go deeper on Resolve Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resolve Therapeutics.

Explore the full profile